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Abstract
Background: Human glucose 6-phosphate dehydrogenase (G6PD), active in both dimer and
tetramer forms, is the key entry enzyme in the pentose phosphate pathway (PPP), providing
NADPH for biosynthesis and various other purposes, including protection against oxidative stress
in erythrocytes. Accordingly haemolytic disease is a major consequence of G6PD deficiency
mutations in man, and many severe disease phenotypes are attributed to G6PD folding problems.
Therefore, a robust refolding method with high recovery yield and reproducibility is of particular
importance to study those clinical mutant enzymes as well as to shed light generally on the refolding
process of large multi-domain proteins.
Results:  The effects of different chemical and physical variables on the refolding of human
recombinant G6PD have been extensively investigated. L-Arg, NADP+ and DTT are all major
positive influences on refolding, and temperature, protein concentration, salt types and other
additives also have significant impacts. With the method described here, ~70% enzyme activity
could be regained, with good reproducibility, after denaturation with Gdn-HCl, by rapid dilution of
the protein, and the refolded enzyme displays kinetic and CD properties indistinguishable from
those of the native protein. Refolding under these conditions is relatively slow, taking about 7 days
to complete at room temperature even in the presence of cyclophilin A, a peptidylprolyl isomerase
reported to increase refolding rates. The refolded protein intermediates shift from dominant
monomer to dimer during this process, the gradual emergence of dimer correlating well with the
regain of enzyme activity.
Conclusion: L-Arg is the key player in the refolding of human G6PD, preventing the aggregation
of folding intermediate, and NADP+ is essential for the folding intermediate to adopt native
structure. The refolding protocol can be applied to produce high recovery yield of folded protein
with unaltered properties, paving the way for future studies on clinical G6PD mutants with folding
defects and providing a useful model system to study the folding process of oligomeric proteins.
Background
Human glucose 6-phosphate dehydrogenase (G6PD; EC
1.1.1.49) catalyses the first and rate-limiting step in the
pentose phosphate pathway. This pathway provides
ribose-5-phosphate (R5P) for the synthesis of nucleotides
and generates NADPH, both generally for biosynthesis
and for more specialised tasks such as protection against
oxidative stress in erythrocytes, where G6PD is particu-
Published: 11 March 2009
BMC Biotechnology 2009, 9:19 doi:10.1186/1472-6750-9-19
Received: 7 October 2008
Accepted: 11 March 2009
This article is available from: http://www.biomedcentral.com/1472-6750/9/19
© 2009 Wang and Engel; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2009, 9:19 http://www.biomedcentral.com/1472-6750/9/19
Page 2 of 10
(page number not for citation purposes)
larly important as the sole source of NADPH. In connec-
tion with this latter role, G6PD deficiency is the most
common human enzymopathy, affecting about 400 mil-
lion people [1,2], and well over 160 different mutations
have been determined at the DNA level [3,4]. Recently,
the elucidation of the 3-D crystal structure of human
G6PD [5,6] has prompted renewed efforts to explain the
effects of these mutations. Of the various possible defects
[7-10], instability is the prime candidate, since the non-
nucleate red blood cells are unable to replace damaged or
aged enzyme molecules, and this would explain why
haemolytic anaemia is the main manifestation of the defi-
ciency. A folding defect has been suggested as being
responsible for the lower stability of clinical G6PD vari-
ants [11-13]. The stability of the protein is also thought to
be critically dependent on the concentration of NADP+
[14,15], which has been clearly shown to be incorporated
into the structure of the folded protein [11,16,17], and
impaired binding of this "structural" NADP+ is thought to
underlie instability in some clinical mutants. A conven-
ient, robust and reliable refolding method giving high
yields for the native enzyme is therefore much needed in
order to investigate differences in folding ability between
G6PD WT and the mutants.
Of previous attempts to refold human G6PD, the most
successful was that of Gomez-Gallego et al. [11], with
apparently about 50% recovery (the figure is not explicitly
reported). However, in their protocol, protein disulphide
isomerase (PDI), the key player, was prepared from
bovine liver through time-consuming and tedious proce-
dures with relatively low yield. In addition, GSH and
GSSG applied in their method are expensive, and most
importantly they did not work in our hands. Therefore, a
detailed study on the refolding of human G6PD has now
been carried out, leading to an easy and feasible protocol
that gives reproducibly high refolding yields, also allow-
ing a thorough survey of the relevant physical parameters
and of chemical additives likely to assist the process.
Results
Unfolding of human G6PD
Native G6PD (2–4 mg/ml), with free or loosely bound
NADP+ previously removed by serial dilution, was dena-
tured by different concentrations of Gdn-HCl in 50 mM
Tris-HCl, pH 7.6, at 30°C and kept reduced by the inclu-
sion of 20 mM DTT. The enzyme activity decreased rap-
idly, and was undetectable after 10 minutes even in 1 M
Gdn-HCl. With lower concentrations of Gdn-HCl (e.g.
0.75 M), the denatured protein precipitated, but the
resulting pellet could be solubilised at higher concentra-
tions of Gdn-HCl (e.g. 4 M). CD results showed that, in
the presence of 4 M Gdn-HCl, after 2 hours all secondary
structure was lost (data not shown) and 4 M Gdn-HCl was
therefore used routinely to denature the protein in the fol-
lowing experiments.
Rate of refolding
Under the various conditions explored, the final extent of
reactivation varied greatly, but in general the process was
slow and required several days in order to achieve comple-
tion. In the absence of any beneficial additive the extent of
recovery was no more than 1 – 2%. In all the detailed
investigations of individual additives below, therefore,
the conditions are already partially optimised by the
inclusion of one of the other beneficial additives at a con-
stant concentration. In general, the major effect of these
additives was on the extent of refolding rather than its
speed.
Effects of L-arginine and DTT
Arginine has long been regarded as a suppressor of protein
aggregation and can increase the solubility of aggregation-
prone molecules [18-21]. The denatured G6PD protein (1
mg/ml) was diluted quickly into refolding buffer (50 mM
Tris, pH 8.0 containing 50 mM NaCl, 200 μM NADP+, 10
mM DTT, and 40 μM PEG 3350) to a final concentration
of 10 μg/ml with addition of different concentrations of
Arg (0–700 mM). The refolding mixture was kept at 25°C
and the recovery of enzyme activity was followed. G6PD
activity was regained slowly but steadily, reaching a maxi-
mum after about 7 days, with 2.6%, 44.3%, 59.4%,
69.5%, 71.1%, 72.2%, 72.1% respectively for 0, 200 mM,
300 mM, 400 mM, 500 mM, 600 mM, and 700 mM Arg
added (Table 1), showing that arginine is a highly benefi-
cial additive for refolding. However, when only added to
the refolding mixture one day after initiating refolding,
Arg was entirely ineffective (data not shown).
Although there are 8 Cys residues in human G6PD, the
native protein contains no disulphide bonds. Therefore,
maintaining a reducing environment during refolding
Table 1: Effects of different concentrations of arginine on the refolding recovery yield.
Added Arg concentration (mM) 0 200 300 400 500 600 700
Refolding yield (%) 2.6 ± 0.1 44.3 ± 3.5 59.4 ± 3.8 69.5 ± 4.1 71.1 ± 4.0 72.2 ± 4.3 72.1 ± 5.1
L-arginine was added into the refolding buffer containing 50 mM NaCl, 200 μM NADP+, 10 mM DTT, 40 μM PEG 3350 in 50 mM Tris, pH 8.0 to 
reach final concentrations of Arg from 0 to 700 mM. The refolding mixture was incubated at 25°C. Activity was monitored over several days and 
the final regain of G6PD activity is recorded.BMC Biotechnology 2009, 9:19 http://www.biomedcentral.com/1472-6750/9/19
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might be crucial. Without addition of DTT, only 24% of
G6PD enzyme activity was recovered even in the presence
of high arginine concentrations, as compared with 72%
with 10 mM DTT included.
In view of their marked effect, 400 mM Arg and 10 mM
DTT were routinely included in the refolding mixtures for
most of the remaining experiments and henceforward a
refolding buffer containing 50 mM Tris, pH 8.0, 50 mM
NaCl, 10 mM DTT, 200 μM NADP+, and 400 mM Arg is
denoted 'standard refolding buffer'.
Effects of NADP+
The 3-D structure of human G6PD clearly shows that it
has both "structural" and "catalytic" NADP+ binding sites
[5,6], with affinities for the nucleotide differing by a factor
of 200 [10,22]. It has also been reported that NADP+ is
required for monomer hybridization and refolding
[11,16,17,23]. Here, NADP+ at different concentrations
was added to the refolding buffer (50 mM Tris, pH 8.0,
containing 50 mM NaCl, 10 mM DTT, 40 μM PEG 3350,
and 400 mM Arg) in order to investigate the effect of the
coenzyme on the refolding process. Without added
NADP+, the recovery yield was only about 10%. As the
concentration of NADP+ increased, more enzyme activity
could be regained in a concentration dependent manner
(Fig. 1). N.B. The lowest coenzyme concentration used in
this experiment was in more than 10-fold molar excess
over enzyme subunits.
Effect of cyclophilin A
Based on the 3-D structure of human G6PD [5,6], the cis/
trans transition of amino acid Pro172 is crucial for the
binding of substrate. Since refolding is so slow, the effect
of cyclophilin A, a peptidylprolyl cis-trans isomerase
reported to facilitate refolding, was investigated. Even
with 0.4 μM cyclophilin A in the standard refolding
buffer, maximal recovery still took about 7 days. The
yield, at about 82%, was about 12% higher than without
cyclophilin A. Proline isomerisation would appear not to
be a major rate limitation here.
Effects of other folding additives
Various protein folding enhancers, i.e. ammonium sul-
phate and certain amino acids such as glycine and proline,
protein aggregation suppressors, i.e. PEG 3350, Triton X-
100, and butanol, and protein stabilizers, i.e. glycerol, tre-
halose, 6-aminohexanoic acid (AHA) and glucose were
added separately in the standard refolding buffer. At the
concentrations used, PEG 3350, butanol, glycerol, treha-
lose and AHA only marginally increased the refolding
Effects of different concentrations of NADP+ on the refolding  recovery yield Figure 1
Effects of different concentrations of NADP+ on the 
refolding recovery yield. NADP+ was added into the 
refolding buffer containing 50 mM NaCl, 400 mM Arg, 10 
mM DTT, and 40 μM PEG 3350 in 50 mM Tris, pH 8.0 to 
reach final NADP+ concentrations from 0 to 400 μM. The 
refolding mixture was incubated at 25°C and the final 
regained G6PD activity was followed.
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Effects of different folding additives on the refolding recovery  yield Figure 2
Effects of different folding additives on the refolding 
recovery yield. Respective additive was added into the 
refolding buffer containing 50 mM NaCl, 200 μM NADP+, 
and 10 mM DTT in 50 mM Tris, pH 8.0 in the presence or 
absence of 400 mM Arg to final concentration of each addi-
tive at 40 μM for PEG 3350, 400 mM for Gly, 400 mM for 
Pro, 400 mM for glucose, 200 mM for (NH4)2SO4, 200 mM 
for trehalose, 200 mM for AHA, 5% for glycerol, 0.05% for 
Triton X-100 and 0.05% for butanol. The refolding mixture 
was incubated at 25°C and the final regained G6PD activity 
was recorded.
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yield in the presence of Arg (grey bars in Fig. 2), and they
were unable to replace Arg in promoting a high refolding
yield (black bars in Fig. 2). Glycine and proline offered no
further improvement in the refolding process, and glucose
and Triton X-100 even appeared to exercise a significant
negative effect.
Effects of salts
Different salts can affect the solubility and stability of pro-
teins. The effects of various kosmotropic and chaotropic
salts in the Hofmeister series [24] were therefore investi-
gated. When the added concentration of these different
salts was 50 mM in the refolding mixture (50 mM Tris, pH
8.0 containing 400 mM Arg, 200 μM NADP+, 10 mM DTT,
40 μM PEG 3350, and 10 μg/ml G6PD), the refolding
yields were undistinguishable, at about 70% for all the
salts (Fig. 3, grey bars). However, at 400 mM, the effects of
the various salts on the refolding were remarkably differ-
ent, with highest activity regained for NaCl (63%) and
NaAc (58%), moderate for the kosmotropic salts Na2SO4
(23%) and Na2HPO4 (22%) and the least for the chao-
tropic salts NaSCN (1.4%) and NaClO4 (2.3%) (Fig. 3,
black bars).
Effects of pH and temperature
Denatured G6PD protein was diluted into refolding
buffer at different pH values ranging from pH 7.5 to pH
8.5 (50 mM Tris, containing 400 mM Arg, 200 μM
NADP+, 10 mM DTT, 50 mM NaCl, and 40 μM PEG
3350). Refolding was carried out at 25°C, 30°C and
37°C. At 25°C, refolding was relatively slow, taking about
one week to reach the maximum activity (Fig. 4). The final
refolding yield at pH 7.5 was about 69%, similar to 71%
at pH 8.0, and only slightly higher than 65% at pH 8.5,
indicating that over this limited range pH is not a critical
variable. At 30°C, refolding was faster in the early stages
than at 25°C, but the highest activities, achieved after 4–
5 days, were only 49% at pH 7.5, 53% at pH 8.0, and 48%
at pH 8.5, respectively, considerably lower than at 25°C.
Surprisingly, correct refolding was severely suppressed at
37°C, with the highest recovery yield at only 13%.
Effect of protein concentration
Protein concentration is also a key issue which could
affect refolding, on the one hand because G6PD exists in
a rapid dimer-tetramer equilibrium, affected by pH and
ionic strength [25], and on the other hand because too
high a concentration may encourage inappropriate aggre-
gation. In order to optimize the conditions, denatured
G6PD was diluted in the standard refolding buffer at final
protein concentrations ranging from 5 μg/ml to 50 μg/ml.
Recovery yields were 54%, 70%, 56%, and 33% for pro-
tein concentrations at 5 μg/ml, 10 μg/ml, 20 μg/ml and 50
μg/ml, respectively. A concentration of ~10 μg/ml thus
appears to be optimal.
Molecular weight of refolded G6PD
Since refolding of G6PD at 25°C is relatively slow, it is
possible to follow the changing quaternary structure of
the refolding protein. Samples were withdrawn at differ-
ent time points during refolding and the apparent molec-
ular weights of native, unfolded and refolding G6PD (100
μl at 0.2 mg/ml) were determined by FPLC. The native
enzyme gave one major peak and one small minor peak
eluting at 12.36 ml and 10.95 ml, corresponding, accord-
ing to the calibration plot, to Mr values of 100.1 kDa and
203.6 kDa (Fig. 5). These figures approximate to the val-
ues for a dimer (118 kDa) and tetramer (236 kDa). As to
the denatured protein, a single dominant peak at 13.78
ml, indicated an Mr value of 50 kDa. This clearly must be
the monomer (59 kDa), although, as with the other two
figures, this one is low by about 15%. After one day of
refolding, another peak with elution volume at 12.36 ml
(dimer) had appeared. As refolding continued, the mono-
mer peak progressively decreased as the dimer peak grew,
until finally, after five days, nearly all the refolded protein
was dimeric. Thus, for the refolded protein, the main peak
with apparent Mr of around 100 kDa was accompanied by
a relative small peak with apparent Mr of around 200 kDa,
the same as the native enzyme (Fig. 5). Another peak, cor-
responding to monomer (50 kDa), was also clearly seen,
indicating that a small amount of denatured protein
Effects of different kosmotropic and chaotropic salts on the  refolding recovery yield Figure 3
Effects of different kosmotropic and chaotropic salts 
on the refolding recovery yield. Different kosmotropes 
and chaotropes were added into the refolding buffer contain-
ing 400 mM Arg, 200 μM NADP+, and 10 mM DTT in 50 mM 
Tris to final concentrations of each salt at 50 and 400 mM 
respectively, and pH was adjusted to 8.0. The refolding mix-
ture was incubated at 25°C and the final regained G6PD 
activity was followed.
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could not be properly refolded, consistent with the maxi-
mal refolding yield at about 70% under current experi-
mental conditions.
Kinetic parameters of refolded G6PD
A refolded G6PD sample was loaded onto the FPLC col-
umn as described above and the eluted protein with Mr
values of 100 kDa and 200 kDa was collected. Detailed
kinetic measurements were made for the refolded G6PD
for comparison with the native enzyme. The specific activ-
ity of the refolded protein was 175 IU/mg, close to 180
IU/mg for the WT enzyme (Table 2). The Dalziel [26]
parameters of the refolded enzyme were derived as
described for the WT enzyme from primary and secondary
plots of the initial rates [9,27]. The kcat value (1/ϕo) of
refolded G6PD (279 s-1) was similar to that for native
G6PD (275 s-1). The Km values for G6P and NADP+ of
refolded G6PD were likewise, within statistical error,
unaltered compared with the native enzyme (Table 2).
Secondary structure of refolded G6PD
The refolded G6PD sample was collected after running an
FPLC column as mentioned above. The CD spectra of
refolded and native G6PD in the far-UV (200–260 nm) at
Effects of temperature and pH on the refolding recovery  yield Figure 4
Effects of temperature and pH on the refolding 
recovery yield. Denatured protein was diluted into the 
refolding buffer containing 50 mM NaCl, 400 mM Arg, 200 
μM NADP+, and 10 mM DTT in 50 mM Tris with pH ranging 
from 7.5 to 8.5. The refolding mixture was incubated at (a) 
25°C, (b) 30°C, and (c) 37°C, respectively and the regained 
G6PD activity was followed.
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Gel-elution profile of native G6PD and refolded G6PD by  FPLC Figure 5
Gel-elution profile of native G6PD and refolded 
G6PD by FPLC. Denatured protein was diluted into the 
refolding buffer containing 50 mM NaCl, 400 mM Arg, 200 
μM NADP+, and 10 mM DTT in 50 mM Tris, pH 7.5 at 25°C. 
Refolded protein samples were withdrawn after incubation 
for 0, 1, 2, 3, 5, and 7 days. 100 μl samples (around 200 μg/
ml) of G6PD refolded protein intermediates and the native 
protein solutions were loaded on a Superdex 200 HR 10/30 
column equilibrated with 0.1 M Tris-HCl, 150 mM NaCl, pH 
7.6. Apparent molecular weights of refolded G6PD: 203.6 
kDa (10.95 ml), 100.1 kDa (12.36 ml), and 50 kDa (13.78 ml).
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25°C were very similar (Fig. 6), indicating that the sec-
ondary structure of the refolded enzyme is indistinguish-
able from that of native G6PD.
Discussion
The optimised protocol developed here reproducibly
gives a high yield of refolded human G6PD and the
refolded enzyme has properties indistinguishable from
those of native G6PD as judged by steady-state kinetics
(Table 2), FPLC studies of quaternary structure (Fig. 5)
and far-UV CD study of secondary structure (Fig. 6). Since
the refolding process is relatively slow, it should be possi-
ble in future to examine the folding intermediates in
detail in order to shed further light on the folding path-
way of this multi-subunit, multiple-domain protein.
Protein folding involves an intramolecular sequence of
events leading to the biological structure, competing with
an intermolecular aggregation process. For oligomeric
proteins this balance is further complicated by the fact
that, whilst aggregation must be avoided, at the same time
oligomerisation to give the final active species is also an
intermolecular process. In order to improve refolding
yields, two types of additive, aggregation suppressors and
folding enhancers [28], have been widely used. Aggrega-
tion suppressors somewhat destabilize the native struc-
ture but prevent aggregation by weakening the
intermolecular hydrophobic interactions. Among these
suppressors, Arg, containing four types of functional
group, i.e. guanidino-, amino-, carboxy-, and methylene-
groups, is the most frequently used. While suppressing
aggregation and increasing the solubility of denatured
proteins [18,20,29,30], it has little effect, in general, on
either the thermodynamic stability of folded proteins or
the refolding kinetics [21,31,32]. In the present study, the
refolding of G6PD was severely impaired without Arg,
with only 2.6% recovery yield, compared with 70% in the
presence of 500 mM Arg (Table 1). Since Lys, as an alter-
native basic amino acid, did not increase refolding yield,
it seems that the guanidino group of Arg plays a critical
role. In addition, since Arg added one day after the initia-
tion of refolding was ineffective, the aggregation that it
presumably prevents must occur in the early stages of
refolding. Other reputed aggregation suppressors, such as
butanol and PEG 3350 increased the refolding yield only
slightly (Fig. 2). As to chemical chaperones, trehalose and
6-aminohexanoic acid did not appear to stabilize the
renatured G6PD as significantly as previously reported
[33]. Moreover, contrary to previous reports that folding
enhancers, including sugars, ammonium sulphate and
certain amino acids, such as glycine and proline [34-36],
can stabilize protein native structure and enhance inter-
molecular interactions, the results for these additives did
not show any positive effects on the refolding yield of
G6PD, indicating possibly that the effects of folding
enhancers are quite specific to individual proteins.
In this study, it is clearly shown that the refolding yield
depends on NADP+ concentration, increasing from 10%
to 70% as the NADP+ added to the refolding buffer is
increased from 0 to 200 μM (Fig. 1). It should be borne in
mind that, although the refolding buffer itself contained
no added NADP+, the denatured protein will still contain
the "structural" NADP+ (1 mol/mol [22]) released during
the denaturation process. Whether only the "structural"
Table 2: Dalziel steady-state kinetic parameters of native and 
refolded G6PD.
Native G6PD Refolded G6PD
Specific activity (IU/mg) 180 ± 10 175 ± 12
ϕo(s) 0.00366 ± 0.00023 0.00358 ± 0.00031
ϕNADP+(μMs) 0.0259 ± 0.0041 0.0249 ± 0.0037
ϕG6P(μMs) 0.191 ± 0.021 0.196 ± 0.026
ϕNADP+G6P(μM2s) 1.61 ± 0.22 1.55 ± 0.18
ϕNADP+G6P/ϕNADP+(μM) 57.98 ± 0.68 62.6 ± 3.4
ϕNADP+G6P/ϕG6P(μM) 7.77 ± 0.68 7.90 ± 0.37
kcat(s-1) 275 ± 18 279 ± 6.8
KmNADP+(μM) 7.07 ± 1.13 6.94 ± 0.34
KmG6P(μM) 52 ± 4 54.7 ± 3.2
kcat/KmNADP+(μM-1 s-1) 39.7 ± 7.5 40.3 ± 2.5
kcat/KmG6P(μM-1 s-1) 5.31 ± 0.69 5.1 ± 0.34
The table shows the four constants of the reciprocal initial-rate 
equation [26] as estimated for wild-type G6PD and refolded enzyme. 
The corresponding of kcat values and the true Km values for both 
substrates are also listed. The parameters in each case were obtained 
from three independent experiments.
Far-UV CD spectra of native G6PD and refolded G6PD Figure 6
Far-UV CD spectra of native G6PD and refolded 
G6PD. Protein concentration is 0.15 mg/ml and the light 
path for CD experiment is 2 mm.
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NADP+  site or both NADP+  binding sites [5,6] are
involved in the refolding process needs to be further
investigated. Normally, the substrate of an enzyme might
help the refolding process, but the study here showed that
G6P had no positive effect, even though our kinetic stud-
ies [27] would indicate that the sugar phosphate substrate
can bind to the folded enzyme in the absence of coen-
zyme at the active site.
The influence of the salt composition of the refolding
solution was also tested. In the Hofmeister series, SCN-,
ClO4
- and I- are categorized as chaotropic ions while SO4
2-
and H2PO4
- are kosmotropic. Kosmotropes stabilize pro-
tein structure by increasing the amount of water interact-
ing with the protein. In contrast, chaotropes destabilize
proteins by breaking down hydrogen bonding and hydro-
phobic interactions but enhancing solubility. When these
salts were present at 400 mM, the differences in the final
G6PD recovery yield became substantial. For the kosmo-
tropes, the refolding yields were 23% for Na2SO4 and 22%
for Na2HPO4. The chaotropes gave extremely low recovery
yields, only 1.4% for NaSCN and 2.3% for NaClO4. In
contrast, salts in the middle of the Hofmeister series gave
much higher recovery yields with 63% for NaCl and 58%
for CH3COONa (Fig. 3). At high concentration, the chao-
tropes 'salt in' the peptide group, and thus interact much
more strongly with the unfolded form of a protein than
with its native form. Consequently, they pull the overall
equilibrium in the direction of unfolding. On the other
hand, high concentrations of kosmotropes strengthen
hydrophobic interactions, increasing the risk of aggrega-
tion. Therefore, a balance of these two opposing effects is
clearly critical for obtaining high recovery yield.
pH, over the range explored, affected the refolding process
only to a minor extent (Fig. 4). This is consistent with the
accepted view that G6PD is stable from pH 7.5 to 9.0, with
maximum activity at pH 8.0 [37]. Temperature, however,
affects the refolding process and recovery yield dramati-
cally. At 25°C, refolding was relatively slow, with the max-
imum 70% activity reached at pH 8.0 after seven days, and
this activity could be maintained for a couple of days. At
30°C, the recovery was faster in the early stages as
expected, but the highest yield, of about 53% after five
days, was less than at 25°C. In contrast, at 37°C, the
recovery yield was very low, only about 13% after one day.
Also the refolded enzyme was very unstable (Fig. 4). The
results suggest that, although the high temperature ini-
tially accelerates refolding, it can also destabilize the
folded enzyme. Again the balance between two opposing
effects becomes quite critical.
The protein concentration in the refolding buffer is also
important in determining the extent of refolding. At low
protein concentration, the chance of protein molecules
interacting to form oligomers is lower. On the other hand,
without denaturant, the protein molecules are prone to
aggregate at high concentrations. It seems that ~10 μg/ml
is the optimal concentration for refolding.
It is interesting to find that the refolding of human G6PD
in vitro is so slow, taking about seven days to complete
even in the presence of peptidylprolyl isomerase. The
results here clearly show that the regain of enzyme activity
is accompanied by the association of monomer to dimer
(Fig. 5). However, the regained activity is not in strict pro-
portion to dimer formation, suggesting that the freshly
formed dimer is not fully active, but becomes active after
conformational change. These intermediates need to be
further investigated in order to understand the relation-
ship between the activity and the quaternary structure of
the refolded protein.
Arg, NADP+ and DTT are indispensable components of
our optimised refolding buffer. However, in the only pre-
vious report of successful refolding of human G6PD [11]
the protocol did not include Arg and DTT but employed
protein disulphide isomerase and GSH/GSSG. The latter
additives were found to be helpful even in the absence of
PDI [23]. In the present study, GSH and GSSG did not
improve refolding (data not shown). Since there are no
disulphide bonds in native human G6PD, PDI is presum-
ably only needed in the refolding mixture if unwanted
disulphide bonds are allowed to form. GSSG is thus likely
to be a negative factor. The maintenance of a high thiol
concentration in our refolding protocol obviates the need
for PDI. The preparation of this component required sev-
eral steps in the previous report and the elimination of
this component is clearly advantageous.
In recent decades, attention has been increasingly focused
on understanding the protein folding process, not only
because misfolding of even a single specific protein in vivo
can lead to severe disease, but also because large-scale pro-
duction of active recombinant proteins is in strong
demand in pharmaceutical and other industrial fields and
often requires refolding of solubilised inclusion bodies.
Among these proteins, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (E.C.1.2.1.12), an important
enzyme in glycolysis, has been extensively studied as a
model. GAPDH is a tetrameric enzyme of identical subu-
nits containing no disulphide bonds, quite similar to the
structural features of G6PD. A systematic study of the var-
iables affecting the refolding of yeast GAPDH by Deal
[38], demonstrated that the optimum refolding condi-
tions required nicotinamide-adenine dinucleotide, a
reducing environment, and low temperature, in good
agreement with the current results for human G6PD. In
addition, pH, ionic strength and protein concentration all
influenced refolding, as found in this study. Recently,BMC Biotechnology 2009, 9:19 http://www.biomedcentral.com/1472-6750/9/19
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more additives have been found to facilitate the refolding
process of rabbit muscle GAPDH, including the E. coli trig-
ger factors, crowding agents (PEG 20 K, Dextran 70, and
BSA), GroEL, protein disulphide isomerase and α-crystal-
lin [39-43]. In the current study, refolding additives, such
as Arg, PEG 3350 and trehalose all assisted refolding.
Thus, although refolding is a complicated process, there
are significant aspects in common for different proteins.
Conclusion
It is widely believed that the majority of clinical mutations
affecting human G6PD result in destabilisation of the
folded native state. It is reasonable to expect this to be
reflected not only in the thermal stability of the native
protein but also in the ability of the unfolded protein to
achieve the folded native state. Our own earlier attempts
[13] to compare the folding abilities of normal human
G6PD and to two clinical mutants, G6PDMahidol and the
very unstable G6PDPlymouth, led to results that were quali-
tatively as expected but nevertheless undermined by the
very low levels of recovery. This stimulated the search for
a simple and robust procedure that would reproducibly
give high refolding yields for the unmutated enzyme. The
protocol developed and assessed here reliably delivers
upwards of 70% recovery of refolded enzyme with identi-
cal characteristics to the native protein. Now that this has
been achieved, we believe that this protocol should be
useful in the assessment and classification of clinical
mutations. We are currently applying the method to sev-
eral such cases.
Methods
Materials
Coenzymes, NADP+ (>98% purity) and NADPH (>98%
purity) were supplied by Apollo Scientific Ltd (UK), 2'5'
ADP-Sepharose 4B was from GE Healthcare, and the FPLC
column, Superdex 200 (10 × 30 cm), was purchased from
Pharmacia (now GE Healthcare). Glucose 6-phosphate,
guanidinium hydrochloride (Gdn-HCl), L-Arginine
monohydrochloride, dithiothreitol (DTT), trehalose, 6-
aminohexanoic acid (AHA), polyethylene glycol (MW
3350), Trizma base, cyclophilin A, and other salts such as
Na2SO4, Na2HPO4, NaH2PO4, CH3COONa, NaI, NaBr,
NaClO4, NaSCN, etc. were all from Sigma and of reagent
grade or better. Spectrophotometric and fluorimetric
measurements were made throughout with a Cary Bio50
spectrophotometer and a Hitachi F-4500 fluorimeter. Pro-
tein secondary structure was examined with a J810 spec-
tropolarimeter from JASCO (UK).
Cloning, expression and purification of recombinant 
human G6PD
Recombinant wild-type human G6PD, over-expressed,
purified and stored as previously described [9,27],
showed a specific activity of 180 IU/mg. The buffer
throughout purification and subsequent procedures was
0.1 M Tris-HCl, pH 7.6, with 5 mM EDTA. 75 μM NADP+
was added to the buffer, both to achieve elution from the
affinity column and also to ensure long-term stability of
the purified enzyme. For the unfolding experiments,
excess NADP+ was rapidly removed by repeated centrifu-
gal filtration through a Centricon YM-50 cone and dilu-
tion in fresh buffer.
Unfolding of recombinant human G6PD
In the unfolding experiments, 8 M Gdn-HCl, dissolved in
50 mM Tris-HCl, pH 7.6, was added to native G6PD to
give a final protein concentration of 1 mg/ml and denatu-
rant concentrations from 1 to 6 M, and 20 mM DTT was
also included in the mixture to maintain reducing condi-
tions. The mixture was kept at 30°C for two hours in order
to denature the protein completely. The extent of denatur-
ation was assessed by spectropolarimetry.
Refolding of recombinant human G6PD
In the refolding experiments, the reduced and denatured
protein was rapidly diluted into the refolding buffer, with
addition of different additives at an appropriate concen-
tration, and kept in sealed tubes at various temperatures.
The enzyme activity was measured at intervals over peri-
ods of up to 10 days, until it ceased to increase, by fluores-
cence assay, following the increase in the production of
NADPH according to WHO guidelines [37]. Excitation
and emission wavelengths were 340 nm and 450 nm
respectively, with 10 nm band-widths for both light paths.
The calculated final refolding recovery yield was based on
the ratio of enzyme activity regained against the enzyme
activity before denaturation. The effects of various addi-
tives and the impacts of pH and temperature on the
refolding process were investigated, and the influence of
different concentrations of arginine, NADP+, salts and
G6PD protein concentration was examined in detail.
FPLC analysis
The molecular weights of G6PD native and refolded pro-
teins were determined by running on an FPLC column
Superdex 200 HR 10/30 equilibrated with 0.1 M Tris-HCl,
150 mM NaCl, pH 7.6 and calibrated with bovine eryth-
rocyte carbonic anhydrase (29 kDa), bovine serum albu-
min (66 kDa), yeast alcohol dehydrogenase (150 kDa),
sweet potato β-amylase (200 kDa), and horse spleen apo-
ferritin (443 kDa) from Sigma Aldrich.
Steady-state kinetic measurement
Steady-state kinetic studies of the refolded protein were
carried out fluorimetrically at 25°C as previously reported
[9,27]. In brief, reaction mixtures contained 0.01 M MgCl2
in 0.1 M Tris-HCl buffer, pH 8.0 with varying amounts of
sugar phosphate and coenzyme in a total volume of 1 ml.
NADP+ concentrations ranged from 1 to 75 μM and G6PBMC Biotechnology 2009, 9:19 http://www.biomedcentral.com/1472-6750/9/19
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concentrations from 10 to 200 μM. Reaction was initiated
by adding enzyme, typically in 10 μl, to give a linear fluo-
rescence increase for at least the first 2 min.
Circular dichroism analysis
Far-UV CD spectra of native and refolded G6PD were
recorded at 25°C on a JASCO J-810 CD spectropolarime-
ter with a thermal Peltier temperature controller using a 2
mm path length cuvette. Refolded G6PD was loaded onto
an FPLC gel filtration column, and eluted protein corre-
sponding to both dimer and tetramer was collected and
concentrated using Centricon 50 filtration cones (Milli-
pore, U.S.A.). A desalting column from Pierce Biotechnol-
ogy was used to decrease salt concentration of the sample.
0.15 mg/ml protein samples of both native and refolded
G6PD were applied to explore the secondary structure by
following changes in the far-UV region (200–260 nm).
Abbreviations
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